Michael Esposito, MD
Interventional Pain Medicine · Vero Beach, FLNPI 1043521198
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $475,474 of the $776,575 with a category attached, or 61.2%. Boston Scientific accounts for 68.9% of it on its own, with 49 other manufacturers making up the rest. Reporting peaked in 2021 at $196,419 and has fallen 61.1% since, to $76,325 in 2025. Among interventional pain medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,530 payments — averaging $507.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$535K
- Abbott$102K
- Nevro Corp.$36K
- Vertiflex, Inc.$29K
- Stimwave Technologies Incorporated$17K
- Medtronic$17K
- plus $42K from 44 others
Across 57 payments — averaging $1336.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$33K
- Abbott$24K
- Medtronic$13K
- Nevro Corp.$5K
Across 3 payments — averaging $54,250 each. An ownership or investment interest held by the physician or an immediate family member.
- Orthofundamentals, LLC$163K
What the payments were for
- Consulting fees$189,24224%
- Speaking & faculty fees$475,47461%
- Travel & lodging$65,7388%
- Food & beverage$45,6246%
- Education$3210%
- Entertainment$1770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Superion Indirect Decompression System$98,243
- SUPERION$93,709
- WaveWriter Alpha Prime 16$76,892
- Neuromodulation Dspsbls and Accs$54,128
- GENERAL PAIN MANAGEMENT$31,704
- SPECTRA WAVEWRITER$31,155
- GENERAL - THERAPIES$27,824
- Superion ISS$27,760
- VERIFLEX$25,075
- WAVEWRITER ALPHA$24,643
- Proclaim Family of SCS IPGs$21,783
- Senza Spinal Cord Stimulation System$17,832
- Omnia$16,373
- StimQ Receiver Stimulator Kit Channel A US w Receiver$16,034
- StimQ Freedom-4A Receiver Kit Channel A US w/ Receiver$16,034
- StimQ Freedom 8A Receiver Kit Channel A US w Receiver$16,034
- Freedom 4A Receiver Kit Channel A US w Receiver$16,034
- Freedom 8A Receiver Kit Channel A US w Receiver$16,034
- PROCLAIM$15,534
- PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A$14,232
How this compares
$776,576 in reported general payments places this provider in the 95th percentile of 278 interventional pain medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 70 | $38,522 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,137 | $37,158 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,314 | $35,872 |
| LyricaPregabalin | 19 | $23,960 |
| Pregabalin | 662 | $20,848 |
| Gabapentin | 852 | $16,956 |
| MovantikNaloxegol Oxalate | 47 | $16,063 |
| OxycontinOxycodone Hcl | 23 | $15,839 |
| Duloxetine Hcl | 448 | $11,058 |
| Buprenorphine | 26 | $8,960 |
| Diclofenac Sodium | 320 | $7,565 |
| Tramadol Hcl | 643 | $6,460 |
| Fentanyl | 59 | $6,405 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 39 | $5,072 |
| Oxycodone Hcl | 228 | $4,896 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $188 | $38,52270 claims |
| PfizerLyrica | $31 | $23,96019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 278 interventional pain medicine providers in Florida.
Other interventional pain medicine in Vero Beach
- Louis RasoJupiter$1.3M
- Ajay AntonyGainesville$1.1M
- Nomen AzeemRiverview$650K
- Stanley GolovacMerritt Island$367K
- Sunil PanchalLutz$363K
- Robert BallPort Charlotte$246K
- Justin MannJacksonville$243K
- Giuseppe PaeseBoca Raton$180K
- Miguel de la GarzaNew Port Richey$138K
- Andrea TrescotEast Palatka$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.